Dr. Reddy’s Laboratories Ltd., an Indian pharma major, has unveiled its robust performance metrics for the Q2 FY24, ending September 30, 2023. Under the guidelines of the International Financial Reporting Standards (IFRS), the pharmaceutical giant reported a notable YoY revenue growth of 9%, emphasizing its strong market positioning. The company’s growth trajectory, especially in regions […]
In a significant development for diabetes treatment in the U.S., Dr. Reddy’s Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces a therapeutic equivalent to the widely prescribed KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets, with the endorsement of the US Food and Drug Administration (FDA). The Indian pharmaceutical […]
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a comprehensive review of its proposed biosimilar rituximab candidate, DRL_RI. This news comes on the heels of similar acceptance from the European Medicines Agency (EMA) and the United Kingdom’s Medicines and […]
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, has announced its entry into the trade generics business in India with the launch of a dedicated division called ‘RGenX’. The introduction of this division aims to provide patients in India with a broader range of affordable pharmaceutical products. By venturing into the trade generics segment, Dr. Reddy’s […]
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a phase 1 clinical trial. The early-stage study, titled ‘A Phase I, Double Blind, Randomized, Parallel-group, Single dose, Three arm, Comparative Pharmacokinetic and Pharmacodynamic Study of Dr. Reddy’s Laboratories’ Tocilizumab (DRL_TC), […]
Indian pharma company Dr. Reddy’s Laboratories said that it has launched Regadenoson Injection 0.4 mg/5 mL in the US market. Approved by the US Food and Drug Administration (FDA), Regadenoson Injection is a generic therapeutic equivalent of Lexiscan (Regadenoson) injection of Astellas US. It is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI). […]
Eris Lifesciences has announced the acquisition of nine cosmetic dermatology brands in the Indian market from Dr. Reddy’s Laboratories for INR 275 crores in cash. According to the Indian pharma company which is based in Ahmedabad, the deal helps supplement and grow its cosmetic dermatology business through the increase of its product offerings. The brands […]
Dr. Reddy’s Laboratories has agreed to acquire the US generic prescription product portfolio of Mayne Pharma Group, an Australian pharma company, in a deal worth up to $105 million. The generic drug portfolio involved in the deal includes around 45 commercial items, four pipeline products, as well as 40 non-marketed approved products, including a variety […]
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a generic of Revlimid, which has been approved by the US Food and Drug Administration (FDA). The Indian pharma company is entitled to first-to-market, 180 days of generic drug exclusivity for the product in 2.5mg and 20mg strengths […]
Dr. Reddy’s Laboratories said that it has signed a licensing deal with New Jersey-based Slayback Pharma for acquiring rights in the latter’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Brimonidine Tartrate Ophthalmic Solution 0.025% is the private label equivalent of Lumify in the US. Lumify, which is an over-the-counter (OTC) eyedrop, can be used for easing the […]